When you donate to Team Kendall or sponsor any Team Kendall riders in RideATAXIA, 100% of your donations go straight to the Friedreich’s Ataxia Research Alliance (FARA). FARA is a national, public, 501(c)(3), non-profit, tax-exempt organization dedicated to curing Friedreich’s ataxia (FA) through research. FARA grants and activities provide support for basic and translational FA research, pharmaceutical/ biotech drug development, clinical trials, and scientific conferences. F

In this video, Kyle Bryant (Friedreich’s Ataxia (FA) patient and RideATAXIA creator) talks FA with Tampa Bay Buccaneers player Ronde Barber. Kyle gives a great explanation of FA and the science behind what causes FA symptoms, while Ronde helps explain those symptoms with metaphors. If you would like additional information about FA, check out all of the About FA page. To learn more about my symptoms and how my case has progressed, see the About Kendall page. If you have any qu

As you probably recall, we just passed the year anniversary of my Friedreich's Ataxia diagnosis (August 19th). To reflect on the past year and how far we have come, I wrote a blog post entitled "What a Difference A Year Makes." Through the power of social media, my post made its way over to the folks at the Friedreich's Ataxia Research Alliance (FARA). Felicia with FARA contacted me a few weeks ago regarding this blog post. She had passed it along to Jen Farmer, the Executive

Doctors with Chondrial Therapeutics LLC are on the verge of a human trial to test a delivery method of a protein called frataxin, which is used by each cell’s power plants—called mitochondria—to convert fat and sugar into energy. Friedreich’s Ataxia (FA) patients’ cells do not produce enough frataxin, causing the central nervous system breakdown. After teaming up with Ron Bartek, founder of the Friedreich’s Ataxia Research Alliance, the research is on track for Phase 1 of the

The Friedreich’s Ataxia Research Alliance (FARA), just released the new summer edition of the FARA newsletter- The Advocate! I recently had the honor and pleasure of speaking with Kyle Bryant, the Founder & Director of Ride Ataxia. Ride Ataxia is a fundraising program of FARA. We discussed Team Kendall’s first appearance in the 2014 Ride Ataxia Dallas for the newsletter! You can see the write up on page 9. There is also a lot of great information about what is going on in the

The Friedreich’s Ataxia (FA) community received even MORE great news today! Edison Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Status to EPI-743 for the treatment of Friedreich’s Ataxia. This status will further accelerate the clinical development of EPI-743 now under way in two phase 2b clinical trials at three sites in the Friedreich's Ataxia Research Alliance (FARA) Collaborative Clinical Research Network. When the FDA

In the monthly newsletter from the Friedreich's Ataxia Research Alliance (FARA), the FA community received great news about a promising drug in development. Edison Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to vatiquinone (EPI-743) for the treatment of Friedreich’s ataxia. Orphan status brings additional momentum and acceleration to the clinical development of EPI-743 now underway at three sites in the FARA Collab

The Friedreich's Ataxia Research Alliance announced today that BioMarin Pharmaceutical, a company with a strong commitment and success in developing treatments for rare diseases, will be taking the Histone DeACetylase (HDAC) inhibitor program forward. Click here to access FARA's press release as well as a press release from Repligen and BioMarin. With this exciting news, we are reminded of the important work our donations fund. Thank you to everyone who has had a part in maki